Physician profile
Tara Ross
NPI 1447801972
$968.39
in general payments reported to CMS, 2019-2025
13 companies · $24.41 in 2025
The $24.41 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $306 · 2022: $431 · 2023: $154 · 2024: $51.77 · 2025: $24.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.72 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $211.94 | 2021-2023 | Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $184.70 | 2021-2022 | |
| Lilly USA, LLC | $118.00 | 2021-2023 | Emgality, Reyvow |
| Glaxosmithkline, LLC. | $45.80 | 2022 | |
| Abbvie INC. | $45.42 | 2023-2024 | |
| Amgen INC. | $35.61 | 2021-2022 | |
| Exact Sciences Corporation | $24.41 | 2025 | Cologuard Collection Kit |
| Exeltis, USA INC. | $22.74 | 2021 | |
| Eisai INC. | $20.00 | 2021 | |
| Horizon Therapeutics Plc | $19.03 | 2022 | |
| Dexcom, INC. | $13.59 | 2022 | |
| Genentech USA, INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.